After obtaining a MSc in Drug Discovery and Safety at the VU Amsterdam, Pieter started working in pharmacovigilance in 2010. He worked as Drug Safety Officer and Senior Safety Scientist for different pharmaceutical companies and NGOs, specializing in Argus configuration and international legislation before he became Manager Affiliate Governance at the QPPV office at Incyte Biosciences in Lausanne, Switzerland. In 2019 he accepted a position as Senior Inspector Pharmacovigilance at the Dutch Health and Youth Care Inspectorate, performing national and EMA inspections.

Camelia has 15 years of experience working in academia, the pharmaceutical industry and in a regulatory agency, in the fields of regulatory affairs, pharmacovigilance and clinical trials. She is a pharmacist by education and has been working at the European Medicines Agency for almost 5 years. In her role Camelia is responsible for the coordination of GCP and pharmacovigilance inspections, taking part in drafting EU guidelines related to GCP and collaborating with international regulatory agencies on inspectional matters. Camelia has a PhD in Pharmaceutical Sciences.

After finishing his medical education in 1978, Bruno Stricker worked as a medical officer at the Netherlands Center for Monitoring of Adverse Reactions to Drugs. In 1987, he defended his thesis on ‘Drug-induced liver injury’ and wrote 2 books about this subject in 1984 and 1991. In 1991, he became head of this center until 1995 when it was changed into the national monitoring center Lareb. As of 1991, he also worked as an associate professor at the Department of Internal Medicine at the Erasmus Medical Center. Since 2001, he is a professor of pharmacoepidemiology at the Erasmus Medical Center, as well as Coordinating Specialist/Inspector for Pharmacovigilance at the Healthcare and Youth Inspectorate.

Anja van Haren holds a Master in Health Policy and Management from the Erasmus University in Rotterdam. Her career at the Medicines Evaluation Board (MEB) in the Netherlands started in 1998 as a Pharmacovigilance assessor. Since 2004 she has been responsible for technical and procedural aspects of expedited Adverse Drug Reaction reporting in pharmacovigilance. In her current position at the MEB as EudraVigilance Coordinator the focus of her work is on ADR reports, signal detection and signal management. Anja is co-chair of the EudraVigilance Expert Working Group, co-chair of the Pharmacovigilance Business Team and representative of the EU in the ICH E2B(R3) and ICH E2D(R1) Expert Working Groups.

Over the past 25 years Wendy has been dedicated to pharmacovigilance. She has broad experience as EU QPPV for generic and innovative products in complex companies. She also has wealth of experience in lobbying and networking in trade associations/working groups. In her current role, Wendy provides pharmacovigilance support to Pharmaceutical Industry and SMEs (startups). She enjoys setting up the PV system and supports in the development of the PSMF with associated documents. Since 2020 Wendy is a trained professional in Transactional Analysis (TA). TA is a theory of human personality and social behavior. TA gives a wealth of options to work with challenges and changes in organisational and personal development.

Fakhredin Sayed Tabatabaei is a medical doctor and epidemiologist, working as Senior Assessor Pharmacovigilance at the Dutch national agency (MEB) for more than 17 years. He is also the chairman of the CMDh HaRP Project (Harmonization of Risk Management Plan). Fakhredin was an active member of the European Pioneer Group drafting the electronic product information (ePI) Key Principles that is published in 2020, and he is currently involved in the ePI Pilot Project in the Netherlands. Besides, he is the MEB representative in the Gravitate Health project, and the Network Subject Matter Expert in the Product Management Services (PMS) project.